

# Iryna Dyagil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/786414/publications.pdf>

Version: 2024-02-01

34  
papers

1,123  
citations

840776

11  
h-index

501196

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1331  
citing authors

#	ARTICLE	IF	CITATIONS
1	CUMULATIVE INCIDENCE OF LYMPHOID AND MYELOID LEUKEMIAS IN DIFFERENT REGIONS OF THE CHERKASSY REGION IN 2001 AND 2014. , 2021, 2, 48-56.	0.1	0
2	The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. Leukemia Research, 2021, 110, 106686.	0.8	0
3	Molecular-defined clonal evolution in patients with chronic myeloid leukemia who were exposed to ionizing radiation following the Chernobyl nuclear disaster. Leukemia, 2020, 34, 645-650.	7.2	4
4	CHRONIC MYELOID LEUKEMIA COURSE IN PERSONS EXPOSED TO IONIZING RADIATION AS A RESULT OF THE CHORNOBYL ACCIDENT. Problemy Radiatsiinoi Medytsyny Ta Radiobiologii, 2020, 25, 443-455.	0.3	2
5	Analysis of immunoglobulin heavy variable chain rearrangement in chronic lymphocytic leukemia patients among Chernobyl clean-up workers. Experimental Oncology, 2020, 42, 172-177.	0.1	1
6	MYC copy number and mRNA expression in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident. Experimental Oncology, 2020, 42, 60-65.	0.1	0
7	Cancers after Chernobyl: From Epidemiology to Molecular Quantification. Cancers, 2019, 11, 1291.	3.7	11
8	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. Blood, 2019, 134, 498-498.	1.4	11
9	Університетський серіал Біологія, 2019, 76, 53-57.	0.1	0
10	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology, 2018, 36, 231-237.	1.6	356
11	Epidemiology of Late Health Effects in Ukrainian Chernobyl Cleanup Workers. Health Physics, 2018, 115, 161-169.	0.5	23
12	Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chernobyl cleanup workers. Environmental Health, 2018, 17, 43.	4.0	11
13	Clinical characteristics of chronic lymphocytic leukemia occurring in chernobyl cleanup workers. Hematological Oncology, 2017, 35, 215-224.	1.7	7
14	Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia. Leukemia Research, 2017, 58, 1-8.	0.8	6
15	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. Blood, 2017, 130, 900-900.	1.4	9
16	Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up. Blood, 2017, 130, 896-896.	1.4	6
17	Chronic Lymphocytic Leukemia in Chernobyl Cleanup Workers. Health Physics, 2016, 111, 186-191.	0.5	6
18	Baseline Characteristics of CML Patients Across Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. Blood, 2014, 124, 3160-3160.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Radiation and the Risk of Chronic Lymphocytic and Other Leukemias among Chernobyl Cleanup Workers. <i>Environmental Health Perspectives</i> , 2013, 121, 59-65.	6.0	106
20	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. <i>Blood</i> , 2013, 122, 2735-2735.	1.4	1
21	High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial. <i>Haematologica</i> , 2012, 97, 1562-1569.	3.5	10
22	Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3486-3492.	1.6	404
23	DNA Repair Polymorphisms in B-cell Chronic Lymphocytic Leukemia in Sufferers of Chernobyl Nuclear Power Plant Accident. <i>Journal of Radiation Research</i> , 2012, 53, 497-503.	1.6	12
24	Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 190-190.	1.4	12
25	Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemiaâ€“BELA Trial. <i>Blood</i> , 2012, 120, 4442-4442.	1.4	3
26	Busulfan Exposure Decrease CCyR Rate On Imatinib Therapy - Impact On Recent Pretreatment. <i>Blood</i> , 2011, 118, 4452-4452.	1.4	0
27	High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. <i>Haematologica</i> , 2010, 95, 908-913.	3.5	28
28	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010, 51, 822-838.	1.3	9
29	An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 208-208.	1.4	23
30	High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival â€“ Final Results of the CELSG Phase III CML11 â€œISTAHITâ€•Trial. <i>Blood</i> , 2010, 116, 2271-2271.	1.4	0
31	Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accidentâ€“With focus on immunoglobulin heavy chain gene analysis. <i>Leukemia Research</i> , 2008, 32, 535-545.	0.8	28
32	CELSG CML 11 â€œISTAHITâ€•Phase III Study â€“ Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase.. <i>Blood</i> , 2008, 112, 1112-1112.	1.4	3
33	Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph+/BCR-ABL+ CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).. <i>Blood</i> , 2007, 110, 1048-1048.	1.4	17
34	Histologic Verification of Leukemia, Myelodysplasia, and Multiple Myeloma Diagnoses in Patients in Ukraine, 1987â€“1998. <i>International Journal of Hematology</i> , 2002, 76, 55-60.	1.6	12